Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
Titel:
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
Auteur:
Zhou, L. Yang, K.W. Zhang, S. Yan, X.Q. Li, S.M. Xu, H.Y. Li, J. Liu, Y.Q. Tang, B.X. Chi, Z.H. Si, L. Cui, C.L. Guo, H.Q. He, Z.S. Guo, J. Sheng, X.